0001192482-20-000418.txt : 20200602
0001192482-20-000418.hdr.sgml : 20200602
20200602185831
ACCESSION NUMBER: 0001192482-20-000418
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200601
FILED AS OF DATE: 20200602
DATE AS OF CHANGE: 20200602
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ciaffoni Joseph
CENTRAL INDEX KEY: 0001443841
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37372
FILM NUMBER: 20938539
MAIL ADDRESS:
STREET 1: C/O ENDO HEALTH SOLUTIONS INC.
STREET 2: 1400 ATWATER DRIVE
CITY: MALVERN
STATE: PA
ZIP: 19355
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC
CENTRAL INDEX KEY: 0001267565
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: VA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 TECHNOLOGY CENTER DRIVE
CITY: STOUGHTON
STATE: MA
ZIP: 02072
BUSINESS PHONE: 781-713-3699
MAIL ADDRESS:
STREET 1: 100 TECHNOLOGY CENTER DRIVE
CITY: STOUGHTON
STATE: MA
ZIP: 02072
FORMER COMPANY:
FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC
DATE OF NAME CHANGE: 20031020
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2020-06-01
0001267565
COLLEGIUM PHARMACEUTICAL, INC
COLL
0001443841
Ciaffoni Joseph
C/O COLLEGIUM PHARMACEUTICAL, INC.
100 TECHNOLOGY CENTER DRIVE
STOUGHTON
MA
02072
1
1
0
0
President and CEO
Common Stock
2020-06-01
4
F
0
4672
21.24
D
204515
D
Common Stock
2020-06-01
4
M
0
64820
8.22
A
269335
D
Common Stock
2020-06-01
4
S
0
70576
21.53
D
198759
D
Common Stock
2020-06-01
4
S
0
100
22.08
D
198659
D
Common Stock
2020-06-02
4
S
0
5761
20.47
D
192898
D
Common Stock
2020-06-02
4
S
0
100
21.3
D
192798
D
Stock Option (Right to Purchase)
8.22
2020-06-01
4
M
0
64820
0
D
2027-05-31
Common Stock
64820
64821
D
Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.05 to $22.02, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (3) and (4).
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.18 to $20.92, inclusive.
64,820 shares under the option are exercisable. The option, initially representing a right to purchase a total of 259,283 shares, vests and becomes exercisable over a four-year period commencing on May 31, 2017. Twenty-five percent (25%) of the option vested and became exercisable on May 31, 2018 and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) at the end of each quarterly period over the remaining three years of the four-year period, subject to the reporting person's continued service with the Issuer.
/s/ Paul Brannelly as Attorney-In-Fact For Joseph Ciaffoni
2020-06-02